Form 4: USANA CCO Neidig Reports RSU Vesting, Tax-Related Sales

USANA Health Sciences Chief Commercial Officer Brent Neidig reported the vesting of restricted stock units and subsequent tax-related sales of common stock over three days in February 2026.

Summary

• Brent Neidig, Chief Commercial Officer of USANA Health Sciences Inc., reported multiple transactions involving the company's common stock and restricted stock units (RSUs).
• On February 6, 2026, Neidig acquired 2,219 shares of common stock from RSU vesting and disposed of 1,102 shares at $21.34 for tax withholding, resulting in 1,117 shares beneficially owned.
• On February 7, 2026, Neidig acquired 1,401 shares of common stock from RSU vesting and disposed of 696 shares at $21.34 for tax withholding, resulting in 1,822 shares beneficially owned.
• On February 8, 2026, Neidig acquired 3,690 shares of common stock from RSU vesting and disposed of 1,753 shares at $21.34 for tax withholding, resulting in 3,759 shares beneficially owned.
• These transactions were made pursuant to a Rule 10b5-1 plan, indicating they were pre-scheduled.
• The RSUs converted represent a contingent right to receive one share of USNA common stock, with vesting dates on the anniversaries of February 6, 2023, February 7, 2022, and February 8, 2024, respectively.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports routine, pre-scheduled executive compensation events (RSU vesting and tax-related sales) and does not indicate any discretionary buying or selling based on new information.

Positives

• The acquisition of common stock through RSU vesting indicates continued equity participation by a key executive.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting pre-planned and automated transactions rather than discretionary sales based on new, non-public information.

Negatives

• A significant portion of the vested shares were immediately sold to cover tax obligations, which is a common practice but reduces the executive's direct ownership increase from the vesting event.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures for publicly traded companies, providing transparency into executive compensation and equity ownership. While these specific transactions are related to RSU vesting and tax withholding, they are common occurrences across various industries where equity compensation is a significant component of executive pay.

Stakeholder Impact

• Shareholders gain transparency into executive equity compensation and ownership changes.
• The company fulfills its regulatory disclosure requirements regarding insider transactions.

Key Dates

Recommendation

The filing details routine, pre-scheduled transactions related to executive compensation (RSU vesting and tax-related sales) under a Rule 10b5-1 plan. These transactions do not reflect discretionary buying or selling based on new material information and therefore do not provide a basis for a change in investment recommendation. The stock's performance should be evaluated based on broader company fundamentals and market conditions.

Keywords

USANA Health Sciences, USNA, Brent Neidig, Chief Commercial Officer, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sales, Rule 10b5-1 Plan